Pfizer is dropping a significant portion of participants from a phase 3 vaccine trial, the company announced on Feb. 17.
Approximately half of the participants are being discontinued from the trial, which is examining the safety and efficacy of an experimental vaccine against Lyme disease, Pfizer and Valneva, a French company, said in a joint statement.
The companies blamed rules violations committed at some of the trial sites, which they said were being run by a third-party contractor.
Good Clinical Practice (GCP) is an international standard developed by the United States and other countries to guide clinical trials. The rules are aimed at running ethical trials….